# Heart Failure Mortality Prediction Model Summary

## Executive Summary

This model predicts the likelihood of death (DEATH_EVENT) in patients with heart failure using clinical and laboratory features. It demonstrates good discrimination with an AUC of 0.86 and balanced accuracy and F1 scores, indicating reliable performance in identifying patients at risk. The underlying data is mostly complete and consistent but contains notable outliers and about 10% anomalous cases, which warrant caution in interpretation.

## Performance

- **AUC:** 0.859
- **Accuracy:** 0.817
- **F1 score (positive class):** 0.667

The model achieves strong discrimination ability (AUC ~0.86), meaning it effectively distinguishes between patients who survive and those who do not. An accuracy of approximately 82% indicates that the model correctly classifies the majority of cases overall. The F1 score of 0.67 reflects a reasonable balance between precision and recall for predicting death events, though there is room for improvement in capturing all positive cases.

## Feature Importance

Feature importance is derived from SHAP values, which quantify each feature's contribution to the model's predictions. The most influential feature is 'time,' likely representing follow-up duration or survival time, with higher values associated with risk. 'Ejection_fraction' is the next most important; lower ejection fraction values increase mortality risk, consistent with clinical understanding. Elevated 'serum_creatinine' levels and older 'age' also increase risk. The presence of 'diabetes' and 'sex' (male/female) further influence risk, with diabetes increasing mortality likelihood. Other features like 'creatinine_phosphokinase', 'serum_sodium', 'smoking', and 'platelets' contribute less but still affect predictions.

## Data Quality Considerations

The data quality status is WARN due to several concerns. While there are no missing or duplicate values and data types are consistent, multiple numeric features exhibit outliers (e.g., creatinine_phosphokinase, serum_creatinine, platelets). Additionally, about 10% of rows were flagged as anomalous by an IsolationForest model, indicating potential unusual patient profiles or data entry issues. These factors may introduce noise or bias, reducing confidence in some predictions and suggesting the need for careful data preprocessing and validation.

## Recommendations

Before deploying this model clinically, consider addressing the outliers through clinical review or statistical methods such as capping or robust scaling to reduce their impact. Investigate the anomalous rows to determine if they represent valid rare cases or errors; exclusion or separate modeling may be warranted. Monitor model performance over time, especially if new data distributions differ. Users should be cautious interpreting predictions for patients with extreme feature values or profiles similar to flagged anomalies. Overall, the model shows promise but requires ongoing evaluation and data quality management for safe clinical use.
